学術雑誌論文 Metabolic analysis of radioresistant medulloblastoma stem-like clones and potential therapeutic targets

Sun, Lue  ,  Moritake, Takashi  ,  Ito, Kazuya  ,  Matsumoto, Yoshitaka  ,  Yasui, Hironobu  ,  Nakagawa, Hidehiko  ,  Hirayama, Aki  ,  Inanami, Osamu  ,  Tsuboi, Koji

12 ( 4 )  , p.e0176162 , 2017-04 , Public Library of Science
ISSN:1932-6203
内容記述
Medulloblastoma is a fatal brain tumor in children, primarily due to the presence of treatment-resistant medulloblastoma stem cells. The energy metabolic pathway is a potential target of cancer therapy because it is often different between cancer cells and normal cells. However, the metabolic properties of medulloblastoma stem cells, and whether specific metabolic pathways are essential for sustaining their stem cell-like phenotype and radioresistance, remain unclear. We have established radioresistant medulloblastoma stem-like clones (rMSLCs) by irradiation of the human medulloblastoma cell line ONS-76. Here, we assessed reactive oxygen species (ROS) production, mitochondria function, oxygen consumption rate (OCR), energy state, and metabolites of glycolysis and tricarboxylic acid cycle in rMSLCs and parental cells. rMSLCs showed higher lactate production and lower oxygen consumption rate than parental cells. Additionally, rMSLCs had low mitochondria mass, low endogenous ROS production, and existed in a low-energy state. Treatment with the metabolic modifier dichloroacetate (DCA) resulted in mitochondria dysfunction, glycolysis inhibition, elongated mitochondria morphology, and increased ROS production. DCA also increased radiosensitivity by suppression of the DNA repair capacity through nuclear oxidization and accelerated the generation of acetyl CoA to compensate for the lack of ATP. Moreover, treatment with DCA decreased cancer stem cell-like characters (e.g., CD133 positivity and sphere-forming ability) in rMSLCs. Together, our findings provide insights into the specific metabolism of rMSLCs and illuminate potential metabolic targets that might be exploited for therapeutic benefit in medulloblastoma.
本文を読む

https://tsukuba.repo.nii.ac.jp/?action=repository_action_common_download&item_id=41333&item_no=1&attribute_id=17&file_no=1

このアイテムのアクセス数:  回

その他の情報